Physician profile

John V Kramer

Foot Surgery · Flemington, NJ

NPI 1548209356

$474.64

in general payments reported to CMS, 2019-2025

8 companies · $5.74 in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$371.24

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Stryker Corporation $226.74 2019-2023 Augment Injectable, Actishield
Urgo Medical North America, LLC $98.98 2024 Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Urgok2
Organogenesis INC. $60.99 2019-2022
Smith+Nephew, INC. $31.86 2023 Grafix Pl, Stravix, Grafix
Nevro Corp. $21.33 2024 Senza
Melinta Therapeutics, LLC $15.00 2019
Celularity INC. $14.00 2019
Musculoskeletal Transplant Foundation INC. $5.74 2025

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John V Kramer

$474.64

in general payments reported 2019-2025

Years
2019-2025
Top company
Stryker Corporation

https://glasscript.com/doctor/777207/john-v-kramer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.